# Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

> **NCT00894868** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 798 (actual)

## Conditions studied

- Congestive Heart Failure
- Type II Diabetes Mellitus

## Interventions

- **DRUG:** vildagliptin
- **DRUG:** placebo of vildagliptin

## Key facts

- **NCT ID:** NCT00894868
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 798 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00894868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00894868, "Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00894868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*